Clinical Trial Detail

NCT ID NCT03579472
Title M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Eribulin + M7824

Age Groups: adult senior

No variant requirements are available.